Cost of Revenue Comparison: Pfizer Inc. vs Galapagos NV

A Tale of Two Companies: Pfizer Inc. vs. Galapagos NV

In the ever-evolving pharmaceutical industry, cost efficiency is paramount. This chart offers a fascinating glimpse into the cost of revenue trends for Pfizer Inc. and Galapagos NV from 2014 to 2023. Over this period, Pfizer's cost of revenue surged by approximately 210%, peaking in 2022, while Galapagos NV experienced a more volatile journey, with a dramatic drop in 2021. Notably, Pfizer's cost of revenue consistently dwarfed that of Galapagos, highlighting its expansive operations. The year 2021 marked a turning point for both companies, with Pfizer's costs skyrocketing by over 250% compared to the previous year, likely due to increased production demands. Meanwhile, Galapagos NV's costs plummeted to a mere fraction of its previous figures, indicating strategic shifts or operational challenges. This comparison underscores the dynamic nature of the pharmaceutical sector and the diverse strategies companies employ to navigate it.